Trump Announces Major Drug Pricing Agreement Aimed At Lowering Costs

President Donald Trump on Friday announced a new agreement with a major pharmaceutical manufacturer that will tie the company’s U.S. drug prices to the lowest rates offered in other developed countries, expanding the administration’s “most-favored-nation” policy for prescription drug costs.

The deal, unveiled during an Oval Office event with AstraZeneca Chief Executive Officer Pascal Soriot, follows a similar arrangement the administration announced in September with Pfizer. It marks the second major pharmaceutical pricing agreement under the White House’s executive order seeking to reduce medication costs for Medicaid and direct-to-consumer purchases.

Under the terms described by the White House, AstraZeneca will provide “most-favored-nation,” or MFN, pricing to all state Medicaid programs, meaning that U.S. patients will pay no more than the lowest price available for the same drugs in other developed countries. The administration said the agreement could save American taxpayers hundreds of millions of dollars annually.

“For many years, Americans have paid the highest prices anywhere in the world for prescription drugs,” Trump said. “Today, AstraZeneca is committing to offer all of their prescription medications to Medicaid at the most-favored-nation price—the lowest price anywhere in the world.”

The administration said the deal will benefit about 9 million patients currently taking AstraZeneca products. It will apply to a range of the company’s medications, including those used to treat asthma, chronic obstructive pulmonary disease (COPD), cardiovascular conditions, and cancer.

The agreement also includes a commitment from AstraZeneca to invest $50 billion in U.S. manufacturing and research and development by 2030. According to a White House fact sheet, the company will build a new pharmaceutical production facility in Charlottesville, Va., which is expected to create 3,600 jobs.

The new site will manufacture active pharmaceutical ingredients used in the company’s respiratory and oncology products.

The administration said the most significant price reductions will be seen in certain respiratory medicines. For example, the COPD treatment BEVESPI AEROSPHERE will reportedly be discounted by an average of 654 percent, while AIRSUPRA, an inhaler for asthma, will see a 96 percent price reduction for direct buyers. The company will also extend discounts to consumers who purchase drugs directly through a federal platform currently being developed by the Department of Health and Human Services.

Friday’s announcement comes just 10 days after Trump revealed a similar MFN agreement with Pfizer, which agreed to provide Medicaid with lower drug prices and participate in the new “TrumpRx” online platform.

That site will allow patients to buy medications directly from manufacturers at substantial discounts compared with retail pharmacy prices. Pfizer said at the time that many of its products, including vaccines, blood thinners, and cancer treatments, would be available at an average discount of 50 percent through the program.

The “most-favored-nation” pricing initiative is part of Trump’s broader effort to reduce the gap between U.S. and foreign prescription drug prices. The administration argues that American consumers have been subsidizing lower costs abroad because foreign governments use price controls and centralized purchasing to negotiate cheaper rates, while U.S. law restricts similar negotiations for federal programs like Medicare.

According to data cited by the White House, Americans pay more than three times as much as residents of other high-income countries for the same brand-name medications, even after accounting for rebates and insurance discounts. Officials said the new pricing model is intended to prevent pharmaceutical companies from charging higher prices domestically while offering lower prices internationally.

In addition to lowering drug costs, the administration said the AstraZeneca agreement will strengthen domestic supply chains and reduce reliance on overseas production. The White House said the Virginia facility would serve as a “strategic hub” for the production of advanced pharmaceutical ingredients used in chronic disease treatments.

The president framed the announcement as part of his ongoing effort to ensure that American patients “get the best deal anywhere in the world” on prescription drugs.

“This agreement will bring immediate relief to millions of Americans struggling with the cost of their medications,” Trump said. “It’s another step in putting American patients first.”

CHAOS On the Set! House Minority Leader Explodes At CNBC Host After He's Cornered Over Obamacare Subsidies

NEW YORK, NY — The polished veneer of the Democrat healthcare narrative shattered on national television this week as House Minority Leader Hakeem Jeffries suffered a visible and vocal meltdown on CNBC’s "Squawk Box." In a segment that has quickly gone viral across the 2026 digital landscape, host Becky Quick executed a clinical cross-examination of the Democrat strategy to ransom the U.S. government over the sunsetting of the Affordable Care Act (ACA) subsidies.

The confrontation marked a pivotal moment in the post-government shutdown political theater, exposing what Speaker Mike Johnson has termed the "Politics of Fear." As Jeffries pivoted, deflected, and eventually erupted in anger, the cold hard reality of the 2026 healthcare crisis was laid bare: a system defined by 60% premium increases, a trillion-dollar price tag, and a Democrat leadership more interested in political leverage than bipartisan solutions.

I. THE CNBC CORNER: "LET’S NOT GO BACK TO THE PAST"

The tension began when Becky Quick pressed Jeffries on the necessity of a bipartisan approach to the looming expiration of taxpayer-provided ACA subsidies. These subsidies, which have artificially suppressed the soaring costs of Obamacare premiums, were strategically set to sunset on December 1, 2025, by the Biden-led Congress—a move critics say was designed to create a "cliff" that would force a Republican-led House into a spending trap.

1. The "Hang Themselves" Accusation

The debate reached a boiling point when Quick directly challenged Jeffries’ motivations for refusing to negotiate on a sustainable, bipartisan reform.

“I don’t think you want to get a deal done,” Quick said, looking directly at a stunned Jeffries. “I think this is something where you’d like to see the rates go higher and allow Republicans to hang themselves with it.”

The assertion struck a nerve. Jeffries, visibly frustrated, abandoned his usual measured tone. “That is a ridiculous assertion! Shame on you!” he shot back, his voice rising as the set descended into chaos. For the American public, the explosion was a tell—a sign that the host had accurately identified the Democrat "Lawfare" strategy being applied to the healthcare sector.

II. THE 60 PERCENT REALITY: OBAMACARE’S FAILED PROMISE

While Jeffries focused on rhetoric, Speaker Mike Johnson utilized his weekly press conference to provide the devastating statistics that have defined the ACA in 2026. The "Affordable" Care Act has become anything but, with the GOP majority revealing that by some estimates, premiums have risen an average of 60% since the program's inception.

1. Subsidies for Insurance Giants

Johnson argued that the "trillion dollars in new spending" demanded by Democrats to reopen the government was not going to patients, but was instead a direct transfer of wealth to insurance companies.

“The Democrats don’t reform Obamacare. They want to subsidize it,” Johnson explained. “That goes mostly to insurance companies, which makes the cost rise further. That’s the Democrats’ plan.”

By continuing to pump taxpayer billions into a broken system, the GOP argues that the radical left is merely inflating the bubble while masking the true, unsustainable cost of the healthcare mandates passed without a single Republican vote in 2010.

III. SAVING MEDICAID: THE AUDIT OF INELIGIBILITY

One of the most significant achievements of the 2026 Republican House has been the aggressive "cleanup" of the Medicaid system—a move Johnson cited as proof that the GOP is the party "fighting to save healthcare."

1. Removing Millions of Ineligible Enrollees

The Speaker revealed that the GOP has successfully moved millions of ineligible enrollees off the Medicaid rolls. This audit was not a cut to services, but a restoration of the program’s original intent.

“We got millions of ineligible enrollees off the program and it preserved it,” Johnson said. “It strengthened Medicaid for the people who rely upon it, which is the elderly, disabled, and young pregnant women.”

By eliminating the fraud, waste, and abuse that had bloated the system under the previous administration, the GOP has ensured that the safety net remains solvent for the most vulnerable Americans. The Democrat opposition to these common-sense audits, Johnson argued, is further evidence that they prioritize "raw numbers" over "quality care."

IV. THE POLITICS OF FEAR VS. THE MANDATE FOR REFORM

The recent government shutdown, which many in the media attempted to frame as a Republican failure, was re-categorized by Johnson as a "false claim" induced by Democrat intransigence. He asserted that the conflict was never truly about healthcare, but about the Radical Left’s fear of losing control over the taxpayer purse.

1. Ransom and Leverage

The December 1 sunset was a "timed bomb" left by the Biden administration. By refusing to work on a bipartisan fix throughout 2025, Jeffries and the House Democrats hoped to use the resulting premium spikes as a political weapon in the 2026 Midterms.

“No, [the shutdown] is not about healthcare,” Johnson declared. “This is about FEAR. Everyone in America understands that this is about something else.” That "something else" is the continued attempt to expand the "Deep State" bureaucracy into every facet of the American economy, using the health of the citizens as collateral.

V. THE 2026 RENAISSANCE: A NEW HEALTHCARE DOCTRINE

As the 2026 Renaissance continues to sweep through Washington, the Trump-aligned GOP is proposing a total shift away from the "subsidy-and-spend" model of the last 15 years. The new doctrine focuses on:

Reducing Costs through Competition: Moving away from state-mandated monopolies.
Increasing Access and Quality: Allowing for more diverse and affordable plan options.
Eliminating Fraud: Continuing the aggressive audits started by Speaker Johnson.

The confrontation on CNBC served as a microcosm of the national debate. On one side, Hakeem Jeffries represents the "Old Guard" of the DNC—relying on explosions of anger and accusations of "shame" to deflect from the fiscal failure of their policies. On the other side, the GOP majority is presenting a "Victorious American" vision: a healthcare system that is sustainable, accountable, and actually affordable.

CONCLUSION: THE END OF THE HEALTHCARE GRIFT

Hakeem Jeffries’ explosion at Becky Quick was not just a moment of bad television; it was the sound of a narrative collapsing. For over a decade, Democrats have used the "Affordable Care Act" as a moral shield to justify trillions in spending. In 2026, with premiums up 60% and the GOP exposing the "insurance company payday," that shield has shattered.

Speaker Mike Johnson and the House GOP have called the Democrats' bluff. By reopening the government without surrendering to the trillion-dollar subsidy demand, they have forced the discussion back to actual reform and fiscal reality.

The era of "subsidizing the failure" is over. As we head toward the 2026 Midterms, the American people are seeing the difference between those who want to "hang" their opponents with higher rates and those who are doing the hard work of saving the safety net for the elderly and disabled. The chaos on the CNBC set was the beginning of the end for the Obamacare grift.